Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the first quarter 2023 financial results and corporate update, set for May 4, 2023. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Arbutus specializes in developing innovative therapeutics for viral diseases, focusing on Hepatitis B, SARS-CoV-2, and other coronaviruses. The company is advancing its lead compound, AB-729, which is currently being tested in phase 2 clinical trials, and is also pursuing oral agents for coronaviruses. An archived webcast will be accessible on the company’s website after the event.
- Scheduled Q1 2023 financial results and update could indicate progress and transparency.
- AB-729's phase 2 trials signify ongoing development and potential market opportunity.
- Focus on HBV and coronaviruses could provide multiple avenues for revenue.
- None.
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its first quarter 2023 financial results and corporate update for Thursday, May 4, 2023. The schedule for the press release and conference call/webcast are as follows:
| • | Q1/2023 Press Release: | Thursday, May 4, 2023 at 7:30 a.m. ET |
| • | Q1/2023 Conference Call/Webcast: | Thursday, May 4, 2023 at 8:45 a.m. ET |
To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. AB-729 is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, (including SARS-CoV-2), for which we have nominated a compound and have begun IND-enabling pre-clinical studies. In addition, we are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma release its Q1 2023 financial results?
What is the focus of Arbutus Biopharma's current drug development?
What is AB-729 and its current status?
How can I access the conference call for Arbutus Biopharma?
